| Name | Title | Contact Details |
|---|
Systems Evolution, Inc. (SEI) is a business and technology consulting firm committed to delivering superior value to local clients since 1992. We pair cutting-edge technologies with custom-tailored solutions to drive powerful business results for some of the most influential companies in the world. We offer the agility, consistency, and personal attention of a local partner while providing the reach and knowledge assets of a national organization. SEI supports critical client needs in areas including Data & Analytics, Technology Enablement, Strategy & Operations, Concept to Delivery, and Security, Risk and Compliance. A 100% employee-owned business, SEI now employs hundreds of consultants across the United States. Our value proposition to both clients and employees is based on a unique business model focused on local delivery, empowerment through technology, fully customized approaches and solutions, and a culture of collaboration.
ePayPolicy is the fastest, easiest and most secure way to move money in the insurance industry. Its never been easier to get paid. There are no contracts, no setup fees, and no hidden fees. Best of all, there is no technical work required to get up and running. Sign up takes only 5 minutes at epaypolicy.com and well have you ready to accept payments online within 24 hours.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
We outfit youth sports teams with customized gear – on time for game time!
Bridge Specialty Group, LLC was launched in February 2021 by Brown & Brown, Inc. to encompass its broad portfolio of wholesale insurance businesses and is focused on bringing the power of its collective size and specialty to the wholesale brokerage marketplace. Composed of more than 25 boutique brands, Bridge Specialty Group is creating a more seamless way to connect the varying needs of our retail partners with the market clout and talents of our wholesale entities. To learn more about Bridge Specialty Group and our team of niche-focused brands, visit our website at bridgespecialtygroup.com.